GTBP - GT Biopharma Inc. Stock Price, Fair Value and News

$0.60-0.16 (-21.05%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GTBP Price Action

Last 7 days

-25%

Last 30 days

-3.2%

Last 90 days

-35.5%

Trailing 12 Months

-78.7%

GTBP RSI Chart

GTBP Valuation

Market Cap

6.4M

Price/Earnings (Trailing)

-0.7

Price/Sales (Trailing)

14.09

EV/EBITDA

-0.5

Price/Free Cashflow

-0.56

GTBP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GTBP Fundamentals

GTBP Revenue

Revenue (TTM)

453.0K

Rev. Growth (Yr)

-62.5%

Rev. Growth (Qtr)

-62.5%

GTBP Earnings

Earnings (TTM)

-9.1M

Earnings Growth (Yr)

8.71%

Earnings Growth (Qtr)

-117.31%

GTBP Profitability

Operating Margin

100.00%

EBT Margin

-3274.39%

Return on Equity

-303.27%

Return on Assets

-214.98%

Free Cashflow Yield

-178.59%

GTBP Investor Care

Shares Dilution (1Y)

376.03%

Diluted EPS (TTM)

-3.34

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	453.0K	0
2024	0	0	637.0K	0
2023	0	0	0	0
2022	0	0	0	0
2021	0	0	0	0
2016	0	0	0	9.8M
2015	0	0	0	0
2014	0	0	0	0
2013	666.0K	990.0K	1.1M	875.0K
2012	0	131.3K	236.7K	342.0K
2011	0	16.0K	21.0K	26.0K
2010	0	0	0	11.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About GT Biopharma Inc.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

CEO	Mr. Michael Martin Breen
WEBSITE	gtbiopharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	2

GT Biopharma Inc. Frequently Asked Questions

What is the ticker symbol for GT Biopharma Inc.? What does GTBP stand for in stocks?

GTBP is the stock ticker symbol of GT Biopharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GT Biopharma Inc. (GTBP)?

As of Wed Dec 03 2025, market cap of GT Biopharma Inc. is 6.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GTBP stock?

You can check GTBP's fair value in chart for subscribers.

Is GT Biopharma Inc. a good stock to buy?

The fair value guage provides a quick view whether GTBP is over valued or under valued. Whether GT Biopharma Inc. is cheap or expensive depends on the assumptions which impact GT Biopharma Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GTBP.

What is GT Biopharma Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, GTBP's PE ratio (Price to Earnings) is -0.7 and Price to Sales (PS) ratio is 14.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GTBP PE ratio will change depending on the future growth rate expectations of investors.